About Us Resources Catalysts Start Free Trial →

Loading…

Day Trader Sniper provides algorithmic alerts and analysis, not trade advice.
Not financial advice. Trade at your own risk.

Quick Links

Download The App Resources Market Feed Stocks

Catalysts About Us Support Privacy policy Terms of use

©2026 Day Trader Sniper - all rights reserved

Home›Catalysts›Regulatory and Clinical

Catalyst Category

Regulatory and Clinical

Live feed of every catalyst classified under Regulatory and Clinical.

CATALYSTS IN FEED

168

AVG MAX MOVE

+116.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

DSMB Efficacy Met FDA 510(k) Cleared FDA Approval FDA Fast Track FDA Meeting FDA Meeting Granted Generic Drug Approved Inconclusive Topline Results IND Cleared for Study IND Filed NDA Resubmission Orphan Drug Designation Positive Subgroup Data Positive Topline Results Primary Endpoint Met SPA Agreement Study Complete Trial Enrollment Complete

Range–Clear

3 catalysts

Regulatory and ClinicalIND FiledJun 11, 2026 · 7:02am ET

PPBTPURPLE BIOTECH LTD.

Purple Biotech Presented New Cancer Immunotherapy Data at EACR 2026

Company stated that IM1240 data support the first human study in 2027.

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Max move

+102.0%

RVOL

3.5x

Max high

$5.98

Fuel

3m

Regulatory and ClinicalIND FiledJun 11, 2026 · 7:02am ET

PPBTPURPLE BIOTECH LTD.+102.0%

Purple Biotech Presented New Cancer Immunotherapy Data at EACR 2026

RVOL

3.5x

Max high

$5.98

Fuel

3m

Regulatory and ClinicalIND FiledMay 7, 2026 · 3:59pm ET

TRAWTraws Pharma, Inc.

Traws Pharma Announces Plans to Advance Hantavirus Treatment Candidates

Company to progress potential clinical candidates for Hantavirus infection.

Regulatory and ClinicalIND FiledMay 7, 2026 · 3:59pm ET

TRAWTraws Pharma, Inc.+52.7%

Traws Pharma Announces Plans to Advance Hantavirus Treatment Candidates

Regulatory and ClinicalIND FiledMay 5, 2026 · 7:36pm ET

IFRXInflaRx N.V.

InflaRx Announces Development of Izicopan for AAV Treatment

Company to focus on oral C5A receptor inhibitor for kidney disorder.

Regulatory and ClinicalIND FiledMay 5, 2026 · 7:36pm ET

IFRXInflaRx N.V.+46.6%

InflaRx Announces Development of Izicopan for AAV Treatment

RVOL

2.1x

Max high

$2.58

Fuel

18m

RVOL

9.2x

Max high

$2.86

Fuel

1h 22m